Bank employee receives six-month sentence for insider trading; Fight over Valeant investments leads two Sequoia Fund independent directors to resign; Merck buys animal vax maker;

@FiercePharma: Aratana unveils branding and partnering plans at investor day. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI: whacking 1,200 jobs, closing plants in US, Ireland, Italy and Spain, but building one in Switzerland. Article | Follow @EricPFierce

@CarlyHFierce: Boehringer ups the ante in IPF drug race with awareness funding. FiercePharmaMarketing report | Follow @CarlyHFierce

> Investments in Valeant Pharmaceuticals ($VRX) led two independent directors of Sequoia Fund, Valeant's largest investor, to resign abruptly. Story

> A former Bank of New York Mellon employee who admitted making $737,000 trading on tips a friend at Merck & Co. ($MRK) supplied him about potential pharma mergers has been ordered to forfeit the profits, pay fines and spend 6 months in jail. Story

> Merck Animal Health has acquired Ames, IA-based animal vaccines maker Harrisvaccines for an undisclosed sum. Release

> With the population aging, a GBI Research report pegs the global market for prostate cancer treatments is to reach $13.6 billion by 2021 from $7.6 billion last year. Item

Medical Device News

@FierceMedDev: Resurgent 23andMe CEO says the genetic testing company is not up for sale. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Sci's Watchman hit by restrictive CMS coverage decision, recall over blood leakage. Story | Follow @VarunSaxena2

@EmilyWFierce: Women are suing Endo Health Solutions and Patheon for child support after contraceptive packaging mishap. FiercePharmaManufacturing story | Follow @EmilyWFierce

> Startup gets $14.3M from U.S. military to eliminate imaging in large vessel trauma procedure. Story

> GE Healthcare partners with an Oregon university for cardiovascular research. News

> Medical marijuana startup develops Keurig-like vaporizer device. Article

Biotech News

@FierceBiotech: Soon-Shiong's NantKwest is spending more on stock buybacks than R&D. Report | Follow @FierceBiotech

@JohnCFierce: Anacetrapib will be either the best come-from-behind PhIII victory or an awfully expensive new cautionary tale about R&D hubris. Hmmmm. | Follow @JohnCFierce

@DamianFierce: Tough day at the Robert J. Coury Global Center, on 1000 Mylan Blvd. More from the WSJ | Follow @DamianFierce

> Regeneron plots a $150M R&D expansion, adding 300 jobs at its New York hub. Article

> Mesoblast disappoints in another below-the-range biotech IPO. Item

> AstraZeneca wins big with fast FDA OK of AZD9291 for lung cancer. News

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.